Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:11:23 EDT Tue 23 Jun 2026
Enter Symbol
or Name
USA
CA



Q:CRMD - CORMEDIX INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRMD - Q0.78.82·8.830.28.825+0.0050.1435.03,6212,7168.75  8.96  8.73117.43  6.12511:52:54Jun 0815 min RT 2¢

Recent Trades - Last 10 of 2716
Time ETExPriceChangeVolume
11:52:54Q8.8290.0091
11:52:48Q8.8250.005200
11:52:48Q8.830.0161
11:52:41Q8.8250.0051
11:52:32Q8.8250.00515
11:52:31Q8.8250.0051
11:52:26Q8.8290.009164
11:52:26Q8.8250.0051
11:52:22Q8.8250.00525
11:52:22Q8.8250.0053

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-08 08:30U:CRMDNews ReleaseU.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin(TM) Patent Litigation
2026-05-15 08:30U:CRMDNews ReleaseCormedix Therapeutics to Participate in two Upcoming Investor Conferences
2026-05-14 07:30U:CRMDNews ReleaseCormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
2026-04-27 07:30U:CRMDNews ReleaseCorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO(TM) for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
2026-04-07 08:30U:CRMDNews ReleaseCorMedix to Participate in Needham Virtual Healthcare Conference
2026-03-05 07:30U:CRMDNews ReleaseCorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-02 08:30U:CRMDNews ReleaseCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
2026-02-12 08:30U:CRMDNews ReleaseCorMedix to Participate in Upcoming Investor Conferences
2026-02-02 08:30U:CRMDNews ReleaseCorMedix Therapeutics Announces Share Repurchase Program
2026-01-29 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
2026-01-09 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-08 08:05U:CRMDNews ReleaseCorMedix Therapeutics Announces Leadership and Board Updates
2026-01-08 08:00U:CRMDNews ReleaseCorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
2025-12-18 08:00U:CRMDNews ReleaseCorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
2025-11-12 16:05U:CRMDNews ReleaseTalphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-12 11:01U:CRMDNews ReleaseStrong Earnings and Biotech Resilience Define the Midweek Momentum
2025-11-12 07:30U:CRMDNews ReleaseCorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
2025-10-31 08:30U:CRMDNews ReleaseCorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
2025-10-23 08:30U:CRMDNews ReleaseCorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath